Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2023 07:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Launches PDAO SEC Chatbot

AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary...
April 19, 2023 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology

The companies are executing on the shared vision of utilizing AI for effective knowledge management in the pharmaceutical research and development industry. AGOURA HILLS, Calif., April 19, 2023 ...
April 17, 2023 07:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE

AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) is providing a summary of its financial results for the year...
April 03, 2023 07:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Announces Release of Pet2DAO Tokens (PDAO)

AGOURA HILLS, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
March 20, 2023 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Announces Pet2DAO Website is Live

PDAO is to Revolutionize Decentralized Autonomous Organization AGOURA HILLS, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or...
March 13, 2023 08:00 ET | Source: Oncotelic Therapeutics, Inc.

High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem

-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC)...
February 06, 2023 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer

AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
January 25, 2023 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer

AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, with a planned IPO of...
January 17, 2023 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Announces the launch of PDAO token

- PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...
December 28, 2022 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Issues Year End Message to Shareholders

– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023- OT-101 commercialization effort expanding on multiple fronts - Manufacturing...